In multivariate Cox analysis, we did not observe any impact of WT1 mutation, WT1 overexpression, or molecular changes in FLT3, NPM1, and CEBPA genes on OS and RFS in AML patients. This evidence concerns the gene FLT3 and acute myeloid leukemia.